Evidence map›Paper›PMID 35833370›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Discovery and SAR analysis of 5-chloro-4-((substituted phenyl)amino)pyrimidine bearing histone deacetylase inhibitors.

Lin Zhang, Yiming Chen, Fahui Li, Lihui Zhang, Jinhong Feng, Lei Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lin ZhangDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Yiming ChenSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Fahui LiDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Lihui ZhangSchool of Stomatology, Weifang Medical University, Weifang, China.
Jinhong FengShandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of sciences), Jinan, China.
Lei ZhangDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Weifang Medical University · CNOcean University of China · CNQilu University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone deacetylases (HDACs) are validated targets for the development of anticancer drugs in epigenetics. In the discovery of novel HDAC inhibitors with anticancer potency, the 5-chloro-4-((substituted phenyl)amino)pyrimidine fragment is assembled as a cap group into the structure of HDAC inhibitors. The SAR revealed that presence of small groups (such as methoxy substitution) is beneficial for the HDAC inhibitory activity. In the enzyme inhibitory selectivity test, compound

Indexed as

Antineoplastic AgentsHistone Deacetylase InhibitorsApoptosisCell Line, TumorCell ProliferationHistone Deacetylase 1Histone Deacetylase 6Histone DeacetylasesPyrimidinesStructure-Activity RelationshipAntineoplastic AgentsHistone Deacetylase 1Histone Deacetylase 6Histone Deacetylase InhibitorsHistone DeacetylasesPyrimidinesanticancerdrug designHistone deacetylaseinhibitorsolid tumour

Identifiers

PMID35833370
PMCPMC9291665
OpenAlexW4285390103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.